Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following nonmyeloablative stem cell transplantation for sickle cell disease

被引：20

作者：

Raj, A ^{[1
]}

Bertolone, S ^{[1
]}

Cheerva, A ^{[1
]}

机构：

[1] Univ Louisville, Sch Med, Dept Pediat, Div Pediat Hematol Oncol, Louisville, KY 40202 USA

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2004年 / 26卷 / 05期

关键词：

autoimmune cytopenia; hematopoietic stem cell transplantation; Rituximab; erythrocytapheresis; sickle cell disease;

D O I：

10.1097/00043426-200405000-00011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Autoimmune hemolytic anemia (AIHA) can occur following hematopoietic stem cell transplantation (HSCT) and may be associated with other cytopenias. It can also occur in the context of chronic red cell transfusion in patients maintained on hypertransfusion regimens. There are an increasing number of reports on the successful treatment of autoimmune cytopenias with the monoclonal anti-CD20 antibody rituximab, including a few patients in a post-HSCT setting. The authors report the successful treatment with rituximab of refractory AIHA following allogeneic nonmyeloablative bone marrow transplantation in a child with sickle cell disease.

引用

页码：312 / 314

页数：3

共 10 条

[1]

CHAKRABARTI S, 2002, HAEMATOLOGICA, V87

[2] Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant [J].

Chen, FE ;

Owen, I ;

Savage, D ;

Roberts, I ;

Apperley, J ;

Goldman, JM ;

Laffan, M .

BONE MARROW TRANSPLANTATION, 1997, 19 (05) :491-495

[3] Stem cell transplantation for sickle cell disease: Can we reduce the toxicity? [J].

Fixler, J ;

Vichinsky, E ;

Walters, MC .

PEDIATRIC PATHOLOGY & MOLECULAR MEDICINE, 2001, 20 (01) :73-86

[4] Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab [J].

Hongeng, S ;

Tardtong, P ;

Worapongpaiboon, S ;

Ungkanont, A ;

Jootar, S .

BONE MARROW TRANSPLANTATION, 2002, 29 (10) :871-872

[5] Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia [J].

Iannone, R ;

Casella, JE ;

Fuchs, EJ ;

Chen, AR ;

Jones, RJ ;

Woolfrey, A ;

Amylon, M ;

Sullivan, KM ;

Storb, RF ;

Walters, MC .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (08) :519-528

[6] Bone marrow transplantation without myeloablation for sickle cell disease. [J].

Krishnamurti, L ;

Blazar, BR ;

Wagner, JE .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (01) :68-68

[7] Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation [J].

Ship, A ;

May, W ;

Lucas, K .

BONE MARROW TRANSPLANTATION, 2002, 29 (04) :365-366

[8] Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease [J].

Talano, JAM ;

Hillery, CA ;

Gottschall, JL ;

Baylerian, DM ;

Scott, JP .

PEDIATRICS, 2003, 111 (06) :E661-E665

[9] Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial [J].

Vichinsky, EP ;

Luban, NLC ;

Wright, E ;

Olivieri, N ;

Driscoll, C ;

Pegelow, CH ;

Adams, RJ .

TRANSFUSION, 2001, 41 (09) :1086-1092

[10] Mechanism of action and resistance to monoclonal antibody therapy [J].

Villamor, N ;

Montserrat, E ;

Colomer, D .

SEMINARS IN ONCOLOGY, 2003, 30 (04) :424-433

← 1 →